FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2367997910> ?p ?o ?g. }

• W2367997910 abstract "Numerous medications are available for the acute treatment of migraine in adults, and some have now been approved for use in children and adolescents in the ambulatory setting. A systematic review of acute treatment of migraine medication trials in children and adolescents will help clinicians make evidence-informed management choices.To assess the effects of pharmacological interventions by any route of administration versus placebo for migraine in children and adolescents 17 years of age or less. For the purposes of this review, children were defined as under 12 years of age and adolescents 12 to 17 years of age.We searched seven bibliographic databases and four clinical trial registers as well as gray literature for studies through February 2016.We included prospective randomized controlled clinical trials of children and adolescents with migraine, comparing acute symptom relieving migraine medications with placebo in the ambulatory setting.Two reviewers screened titles and abstracts and reviewed the full text of potentially eligible studies. Two independent reviewers extracted data for studies meeting inclusion criteria. We calculated the risk ratios (RRs) and number needed to treat for an additional beneficial outcome (NNTB) for dichotomous data. We calculated the risk difference (RD) and number needed to treat for an additional harmful outcome (NNTH) for proportions of adverse events. The percentage of pain-free patients at two hours was the primary efficacy outcome measure. We used adverse events to evaluate safety and tolerability. Secondary outcome measures included headache relief, use of rescue medication, headache recurrence, presence of nausea, and presence of vomiting. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created 'Summary of findings' tables.We identified a total of 27 randomized controlled trials (RCTs) of migraine symptom-relieving medications, in which 9158 children and adolescents were enrolled and 7630 (range of mean age between 8.2 and 14.7 years) received medication. Twenty-four studies focused on drugs in the triptan class, including almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan + naproxen sodium, and zolmitriptan. Other medications studied included paracetamol (acetaminophen), ibuprofen, and dihydroergotamine (DHE). More than half of the studies evaluated sumatriptan. All but one study reported adverse event data. Most studies presented a low or unclear risk of bias, and the overall quality of evidence, according to GRADE criteria, was low to moderate, downgraded mostly due to imprecision and inconsistency. Ibuprofen was more effective than placebo for producing pain freedom at two hours in two small studies that included 162 children (RR 1.87, 95% confidence interval (CI) 1.15 to 3.04) with low quality evidence (due to imprecision). Paracetamol was not superior to placebo in one small study of 80 children. Triptans as a class of medication were superior to placebo in producing pain freedom in 3 studies involving 273 children (RR 1.67, 95% CI 1.06 to 2.62, NNTB 13) (moderate quality evidence) and 21 studies involving 7026 adolescents (RR 1.32, 95% CI 1.19 to 1.47, NNTB 6) (moderate quality evidence). There was no significant difference in the effect sizes between studies involving children versus adolescents. Triptans were associated with an increased risk of minor (non-serious) adverse events in adolescents (RD 0.13, 95% CI 0.08 to 0.18, NNTH 8), but studies did not report any serious adverse events. The risk of minor adverse events was not significant in children (RD 0.06, 95% CI - 0.04 to 0.17, NNTH 17). Sumatriptan plus naproxen sodium was superior to placebo in one study involving 490 adolescents (RR 3.25, 95% CI 1.78 to 5.94, NNTB 6) (moderate quality evidence). Oral dihydroergotamine was not superior to placebo in one small study involving 13 children.Low quality evidence from two small trials shows that ibuprofen appears to improve pain freedom for the acute treatment of children with migraine. We have only limited information on adverse events associated with ibuprofen in the trials included in this review. Triptans as a class are also effective at providing pain freedom in children and adolescents but are associated with higher rates of minor adverse events. Sumatriptan plus naproxen sodium is also effective in treating adolescents with migraine." @default.
• W2367997910 created "2016-06-24" @default.
• W2367997910 creator A5006405191 @default.
• W2367997910 creator A5010229710 @default.
• W2367997910 creator A5019427053 @default.
• W2367997910 creator A5023529246 @default.
• W2367997910 creator A5026319654 @default.
• W2367997910 creator A5047161978 @default.
• W2367997910 creator A5049130892 @default.
• W2367997910 creator A5065476871 @default.
• W2367997910 creator A5087311746 @default.
• W2367997910 date "2016-04-19" @default.
• W2367997910 modified "2023-10-12" @default.
• W2367997910 title "Drugs for the acute treatment of migraine in children and adolescents" @default.
• W2367997910 cites W1203656755 @default.
• W2367997910 cites W1600827843 @default.
• W2367997910 cites W1965827615 @default.
• W2367997910 cites W1979985299 @default.
• W2367997910 cites W1984321707 @default.
• W2367997910 cites W1990366328 @default.
• W2367997910 cites W1991489398 @default.
• W2367997910 cites W1992437247 @default.
• W2367997910 cites W1995175988 @default.
• W2367997910 cites W1996945765 @default.
• W2367997910 cites W2000419697 @default.
• W2367997910 cites W2007669780 @default.
• W2367997910 cites W2012957539 @default.
• W2367997910 cites W2013013535 @default.
• W2367997910 cites W2013563301 @default.
• W2367997910 cites W2015016837 @default.
• W2367997910 cites W2016011428 @default.
• W2367997910 cites W2022293527 @default.
• W2367997910 cites W2033450638 @default.
• W2367997910 cites W2039418122 @default.
• W2367997910 cites W2039874384 @default.
• W2367997910 cites W2040362534 @default.
• W2367997910 cites W2050326182 @default.
• W2367997910 cites W2051283521 @default.
• W2367997910 cites W2067351273 @default.
• W2367997910 cites W2067863212 @default.
• W2367997910 cites W2068370202 @default.
• W2367997910 cites W2068520581 @default.
• W2367997910 cites W2074316560 @default.
• W2367997910 cites W2078402149 @default.
• W2367997910 cites W2086385833 @default.
• W2367997910 cites W2091858211 @default.
• W2367997910 cites W2096431011 @default.
• W2367997910 cites W2101755887 @default.
• W2367997910 cites W2111937143 @default.
• W2367997910 cites W2114508192 @default.
• W2367997910 cites W2116593011 @default.
• W2367997910 cites W2118874378 @default.
• W2367997910 cites W2119553926 @default.
• W2367997910 cites W2126930838 @default.
• W2367997910 cites W2127869701 @default.
• W2367997910 cites W2136038775 @default.
• W2367997910 cites W2136360992 @default.
• W2367997910 cites W2142401871 @default.
• W2367997910 cites W2149253174 @default.
• W2367997910 cites W2152007006 @default.
• W2367997910 cites W2155727751 @default.
• W2367997910 cites W2157823046 @default.
• W2367997910 cites W2159706027 @default.
• W2367997910 cites W2161792711 @default.
• W2367997910 cites W2162104155 @default.
• W2367997910 cites W2163315196 @default.
• W2367997910 cites W2166291278 @default.
• W2367997910 cites W2168181898 @default.
• W2367997910 cites W2316628216 @default.
• W2367997910 cites W2769724041 @default.
• W2367997910 cites W4240693379 @default.
• W2367997910 cites W4247292047 @default.
• W2367997910 cites W4298184796 @default.
• W2367997910 cites W49157362 @default.
• W2367997910 doi "https://doi.org/10.1002/14651858.cd005220.pub2" @default.
• W2367997910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6516975" @default.
• W2367997910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27091010" @default.
• W2367997910 hasPublicationYear "2016" @default.
• W2367997910 type Work @default.
• W2367997910 sameAs 2367997910 @default.
• W2367997910 citedByCount "36" @default.
• W2367997910 countsByYear W23679979102016 @default.
• W2367997910 countsByYear W23679979102017 @default.
• W2367997910 countsByYear W23679979102018 @default.
• W2367997910 countsByYear W23679979102019 @default.
• W2367997910 countsByYear W23679979102020 @default.
• W2367997910 countsByYear W23679979102021 @default.
• W2367997910 countsByYear W23679979102022 @default.
• W2367997910 countsByYear W23679979102023 @default.
• W2367997910 crossrefType "journal-article" @default.
• W2367997910 hasAuthorship W2367997910A5006405191 @default.
• W2367997910 hasAuthorship W2367997910A5010229710 @default.
• W2367997910 hasAuthorship W2367997910A5019427053 @default.
• W2367997910 hasAuthorship W2367997910A5023529246 @default.
• W2367997910 hasAuthorship W2367997910A5026319654 @default.
• W2367997910 hasAuthorship W2367997910A5047161978 @default.
• W2367997910 hasAuthorship W2367997910A5049130892 @default.
• W2367997910 hasAuthorship W2367997910A5065476871 @default.
• W2367997910 hasAuthorship W2367997910A5087311746 @default.
• W2367997910 hasBestOaLocation W23679979102 @default.

• next